0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV50.32%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.11Leverage Ratio--Theta--Rho--Eff Leverage--Vega
IDEAYA Biosciences Stock Discussion
Major FDA Breakthrough: IDEAYA's Eye-Saving Cancer Drug Advances to Phase 3 Trial
Breakthrough: First-in-Class Cancer Drug Combination Shows Promise in Bladder Cancer Study
Breakthrough Cancer Treatment: IDEAYA's IDE275 Targets Major Tumor Types with GSK Backing
Major Clinical Trial Update: IDEAYA's Novel Cancer Drug Targets 48,000 Annual NSCLC Cases
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for a potential first-in-class B7H3/PTK7 topo-I-payload BsADC program. B7H3/PTK7 has been found to be co-expressed in multiple solid tumor types, including double-digit percent prevalence in...
📊⚡️📊
No comment yet